Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Asperloxine A (HB3776)
Description:Natural benzodiazepine with anti-inflammatory action
Purity:>98%
Aspterric acid (HB3779)
Description:Antibiotic. Pollen growth and development inhibitor.
Purity:>95%
Azidothymidine (HB4602)
Description:Selective reverse transcriptase inhibitor with anti-HIV activity. Decreases CRISPR-mediated homology directed repair (HDR) and enhances gene knockout efficiency.
Purity:>98%
Bafilomycin A1 (HB1125)
Description:Highly potent, selective V-ATPase inhibitor. Autophagy inhibitor.
Purity:>98%